|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 1.060 USD | +2.91% |
|
+3.92% | -21.48% |
| 09-14 | Ocugen Insider Sold Shares Worth $589,110, According to a Recent SEC Filing | MT |
| 09-01 | Ocugen Doses First Patient in Trial of Potential Eye Disease Drug | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 359M | - | - | - | ||
| 46.28B | |||||
| 43.85B | |||||
| 40.93B | - | - | - | - | - |
| 39.89B | |||||
| 29.5B |
- Stock Market
- Stocks
- OCGN Stock
- Charts Ocugen, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
